<DOC>
	<DOCNO>NCT02881086</DOCNO>
	<brief_summary>A phase IV study primary goal optimize therapy adult patient acute lymphoblastic leukemia lymphoblastic lymphoma ( LBL ) dose time intensive , pediatric base chemotherapy , risk adapt stem cell transplantation ( SCT ) minimal residual disease ( MRD ) base individualised intensified therapy . Study evaluate role asparaginase intensification , extend use rituximab use nelarabine consolidation therapy T-ALL phase III-part study . Furthermore two randomisation focus role central nervous system ( CNS ) irradiation combination intrathecal therapy versus intrathecal therapy B-precursor ALL/LBL role SCT high-risk patient molecular complete remission . Finally new , dose reduce induction therapy combination Imatinib evaluate Ph/BCR-ABL positive ALL .</brief_summary>
	<brief_title>Optimization Therapy Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Individualised , Targeted Intensified Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Acute lymphoblastic leukemia ( proB , common , preB , early T , thymic T , mature T ) Lymphoblastic lymphoma ( B Tlineage ) Age 1855 yr Written inform consent Adequate contraception specify per protocol Severe comorbidity leukemia associate complication Late relapse pediatric ALL ALL second malignancy Cytostatic pretreatment Pregnancy breast feeding Severe psychiatric illness circumstance may compromise cooperation patient Participation clinical trial interfere study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Lymphoblastic lymphoma</keyword>
	<keyword>Nelarabine</keyword>
	<keyword>BCR-ABL</keyword>
	<keyword>MRD</keyword>
	<keyword>PEG-Asparaginase</keyword>
	<keyword>Rituximab</keyword>
</DOC>